A carregar...
Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma
As CD20 has become an established target for treating B‐cell malignancies, there is interest in developing anti‐CD20 antibodies with different functional activity from rituximab that might translate into improved efficacy. Obinutuzumab (GA101) is a glycoengineered, humanized type II anti‐CD20 monocl...
Na minha lista:
| Publicado no: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7657177/ https://ncbi.nlm.nih.gov/pubmed/23046388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12040 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|